• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
TREAT-NMD

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Conference

What We Do

Home / What We Do

What We Do

We provide an infrastructure that is accelerating research and therapy development, increasing collaboration, improving patient care and helping to support ‘clinical trial readiness’ on an international scale.

TREAT-NMD is internationally recognized for its key role in successfully addressing some of the major issues that face therapeutic development in NMDs. We have a strong track record of advising the scientific and medical community, as well as providing the pharmaceutical industry with essential go-to resources – including education, masterclasses, clinical trial assistance and global data provision – to advance novel treatments for neuromuscular conditions.

Advisory Committee for Therapeutics

Evaluating the therapeutic potential of drugs to optimise their design and development. 

More Info

Global Registry Network

A federated network of 67 individual, independent, national (or regional) patient registries that collect data on neuromuscular patients from more than 61 countries worldwide. 

More Info

Education

Giving healthcare providers greater understanding of the diagnosis and management of neuromuscular diseases.

More Info

Post-Marketing Surveillance

TREAT-NMD contributes to post-marketing surveillance in the neuromuscular field by acting as an independent partner of the Life Sciences Industry and Clinical Research Organisations to facilitate and contribute to international, disease specific PMS systems and processes to fulfil regulatory requirements.

More Info

Core Datasets

TREAT-NMD have published datasets for 5 diseases: Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Myotonic Dystrophy (DM), Spinal Muscular Atrophy (SMA), and Limb Girdle Muscular Dystrophy (LGMD).

More Info

Primary Sidebar

  • What We Do
  • Advisory Committee for Therapeutics
    • Advisory Committee for Therapeutics
    • Members of the Advisory Committee for Therapeutics
    • Past Applicants
  • Global Registry Network
    • The Global Registry Network
    • Global Data systems Oversight Committee – TGDOC
    • Members of the Registry Network
  • Core Datasets
    • Core Datasets
    • DM dataset
    • DMD dataset
    • FSHD dataset
    • LGMD dataset
    • SMA dataset
  • Education
    • Education
    • Masterclasses
    • E-learning Platform
    • Endorsement of external programmes
  • Post-Marketing Surveillance
    • Post-Marketing Surveillance
    • STRIDE Registry

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter Sign Up

Sign up to our monthly newsletter

Connect

info@treat-nmd.com
TREAT NMD © 2023
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
    • Back
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
    • Back
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • Past Applicants
      • Back
    • The Global Registry Network
      • Members of the Registry Network
      • Back
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
      • Back
    • Education
      • Masterclasses
      • E-learning Platform
      • Endorsement of External Programmes
      • Back
    • Post-Marketing Surveillance
    • Back
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
      • Back
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
        • Back
      • Back
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • FSHD Care
      • SMA Care
      • Back
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
        • Back
      • Back
    • Social and Ethical Issues
    • Back
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Conference
    • Back